PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
A Phase II, Double-blind, Randomised, Placebo-controlled Study of the AKT Inhibitor AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer (PAKT).
Sponsor: AstraZeneca
Listed as NCT02423603, this PHASE2 trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 12 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 7 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Sep 2019 — Mar 2020 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
May 2017 — Sep 2017 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Cancer Research UK
- Queen Mary University of London
For direct contact, visit the study record on ClinicalTrials.gov .